Carvedilol induces endogenous hydrogen sulfide tissue concentration changes in various mouse organs

Folia Biologica

Volumn 59, Issue 3-4, 2011, Pages 151-155

  Wiliński, Bogdan ^a   Wiliński, Jerzy ^a   Somogyi, Eugeniusz ^a   Piotrowska, Joanna ^a   Góralska, Marta ^a   Macura, Barbara ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Adrenergic beta antagonists; Carvedilol; Hydrogen sulfide; Mice; Nitric oxide

Indexed keywords

AVEDOL; C REACTIVE PROTEIN; CARVEDILOL; GELATINASE A; GELATINASE B; HYDROGEN SULFIDE; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TISSUE LEVEL; FEMALE; HEART; KIDNEY; LIVER; MOUSE; NONHUMAN; SPECTROPHOTOMETRY; SWISS JAMES LAMBERT MOUSE;

MUS;

EID: 80051677014     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: 10.3409/fb59_3-4.151-155     Document Type: Article

References (33)

1. AFONSO R. A., PATARRAO R. S., MACEDO M. P., CARMO M. M. 2006. Carvedilol's actions are largely mediated by endogenous nitric oxide. Rev. Port. Cardiol. 25: 911-917.
2. AROZAL W., WATANABE K., VEERAVEEDU P. T., MA M., THANDAVARAYAN R. A., SUKUMARAN V., SUZUKI K., KODAMA M., AIZAWA Y. 2010. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274: 18-26.
3. BAKRISG. L., HART P., RITZ E. 2006. Beta blockers in the management of chronic kidney disease. Kidney Int. 70: 1905-1913.
4. BELLENGER N. G., RAJAPPAN K., RAHMAN S. L., LAHIRI A., RAVAL U., WEBSTER J., MURRAY G. D., COATS A. J., CLELAND J. G., PENNELL D. J. 2004. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascularmagnetic resonance study. Heart 90: 760-764.
5. BILSKA A., ICIEK M., KWIECIEŃ I., KANIECKI K., PALIBOREKM., SOMOGYI E., PIOTROWSKA J., WILIŃSKI B., GÓRALSKA M., SREBRO Z., WŁODEK L. 2010. Effects of aspirin on the levels of hydrogen sulfide and sulfane sulfur in mouse tissues. Pharmacol. Rep. 62: 304-310.
6. CHAKRABORTY S., SHUKLA D., MISHRA B., SINGH S. 2010. Clinical updates on carvedilol: a first choice beta-blocker in the treatment of cardiovascular diseases. Expert. Opin. Drug Metab. Toxicol. 6: 237-250.
7. DAWN B., BOLLI R. 2002. Role of nitric oxide in myocardial preconditioning. Ann. N. Y. Acad. Sci. 962: 18-41.
8. ELROD J. W., CALVERT J. W., MORRISON J., DOELLER J. E., KRAUSD. W., TAOL., JIAOX., SCALIAR., KISSL., SZABOC., KIMURA H., CHOW C. W., LEFER D. J. 2007. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc. Natl. Acad. Sci. U.S.A. 104: 15560-15565.
9. FIORUCCI S., ANTONELLI E., MENCARELLI A., ORLANDI S., RENGA B., RIZZO G., DISTRUTTI E., SHAH V., MORELLI A. 2005. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology 42: 539-548.
10. FIORUCCI S., DISTRUTTI E., CIRINO G., WALLACE J. L. 2006. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 131: 259-271.
11. HEMSTREET B. A. 2004. Evaluation of carvedilol for the treatment of portal hypertension. Pharmacotherapy 24: 94-104.
12. ISHIGAMI M., HIRAKI K., UMEMURA K., OGASAWARA Y., ISHII K., KIMURA H. 2009. A source of hydrogen sulfide and a mechanism of its release in the brain. Antioxid. Redox. Signal 11: 205-214.
13. KALINOWSKI L., DOBRUCKI L. W., SZCZEPAŃSKA-KONKEL M., JANKOWSKI M., MARTYNIEC L., ANGIELSKI S., MALIŃSKI T. 2003. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107: 2747-2752.
14. KOSTKA-JEZIERNY K., TYKARSKIA. 2009. Carvedilol. The library of the Arterial Hypertension - Journal of the Polish society of Hypertension. 1. Gdańsk, Via Medica. 1-50. (In Polish).
15. LI L., HSU A., MOORE P. K. 2009. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation - a tale of three gases! Pharmacol. Ther. 123: 386-400.
16. OH G. S., PAE H. O., LEE B. S., KIM B. N., KIM J. M., KIM H. R., JEON S. B., JEON W. K., CHAE H. J., CHUNG H. T. 2006. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic. Biol. Med. 41: 106-119.
17. ŁOWICKA E., BEŁTOWSKI J. 2007. Hydrogen sulfide (H2S) - the third gas of interest for pharmacologists. Pharmacol. Rep. 59: 4-24.
18. PREDMORE B. L., LEFER D. J. 2010. Development of hydrogen sulfide-based therapeutics for cardiovascular disease. J. Cardiovasc. Transl. Res. 3: 487-498.
19. QU K., LEE S. W., BIAN J. S., LOW C. M., WONG P. T. 2008. Hydrogen sulfide: neurochemistry and neurobiology. Neurochem. Int. 52: 155-165.
20. RODRIGUES M. A., RODRIGUES J. L., MARTINS N. M., BARBOSA F., CURTI C., SANTOS N. A., SANTOS A. C. 2010. Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion 10: 46-53.
21. ROMEO F., LI D., SHI M., MEHTA J. L. 2000. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc. Res. 45: 788-794.
22. RUFFOLO R. R., Jr., BOYLE D. A., VENUTI R. P., LUKAS M. A. 1993. Preclinical and clinical pharmacology of carvedilol. J. Hum. Hypertens. 7 Suppl 1: S2-15.
23. SEN U., BASU P., ABE O. A., GIVVIMANI S., TYAGI N., METREVELI N., SHAH K. S., PASSMORE J. C., TYAGI S. C. 2009. Hydrogen sulfide ameliorates hyperhomocysteinemia--associated chronic renal failure. Am. J. Physiol. Renal. Physiol. 297: F410-419.
24. SHIBUYA N., TANAKA M., YOSHIDA M., OGASAWARA Y., TOGAWAT., ISHIIK., KIMURAH. 2009. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid. Redox. Signal. 11: 703-714.
25. SIEGEL L. M. 1965. A Direct Microdetermination for Sulfide. Anal. Biochem. 11: 126-132.
26. SODHA N. R., CLEMENTS R. T., FENG J., LIU Y., BIANCHI C., HORVATH E. M., SZABO C., STAHL G. L., SELLKE F. W. 2009. Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury. J. Thorac. Cardiovasc. Surg. 138: 977-984.
27. SOMOGYI E., PIOTROWSKA J., RZESZUTKO W. 2008. An effect of some parameters of the determination of the hydrogen sulfide in pig liver and brain on the obtained results. Farm. Prz. Nauk. 5: 33-36. (In Polish with English summary).
28. SREBRO Z., SOMOGYI E., WILIŃSKI B., GÓRALSKA M., WILIŃSKI J., SURA P. 2006. Aspirin augments the concentration of endogenous hydrogen sulfide in mouse brain and liver. Folia Med. Cracov. 47: 87-91.
29. SUN Y. G., CAO Y. X., WANG W. W., MA S. F., YAO T., ZHU Y. C. 2008. Hydrogen sulphide is an inhibitor of L-type calcium channels and mechanical contraction in rat cardiomyocytes. Cardiovasc. Res. 79: 632-641.
30. WANG J., ONO K., DICKSTEIN D. L., ARRIETA-CRUZ I., ZHAO W., QIAN X., LAMPARELLO A., SUBNANI R., FERRUZZI M., PAVLIDES C., HOL., HOF P. R., TEPLOWD. B., PASINETTI G. M. 2010. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol. Aging., doi:10.1016/j. neurobiolaging.2010.05.004. Published online July 1.
31. WILIŃSKI B., WILIŃSKI J., SOMOGYI E., GÓRALSKA M., PIOTROWSKA J. 2010. Ramipril affects hydrogen sulfide generation in mouse liver and kidney. Folia Biol. (Kraków) 58: 177-180.
32. WILIŃSKI J., SOMOGYI E., GÓRALSKA M., WILIŃSKI B., CZARNECKA D. 2008. Ramipril enhances the endogenous hydrogen sulfide tissue concentration in mouse heart and brain. Folia Med. Cracov. 3-4: 123-130.
33. XIA M., CHEN L., MUHR. W., LI P. L., LI N. 2009. Production and actions of hydrogen sulfide, a novel gaseous bioactive substance, in the kidneys. J. Pharmacol. Exp. Ther. 329: 1056-1062.